For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...